KNSA

Kiniksa Pharmaceuticals International, plc

NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic

$78.08-2.16%

Key metrics

Market cap: $6.09B
P/E: 80.5x
Forward P/E: 48.3x
P/B: 9.3x
Dividend yield: —
EPS: $0.97
ROE: 14.04%
Profit margin: 9.59%
Revenue growth: +55.40%
Beta: 0.09
52-week high: $82.94
52-week low: $33.45

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Employees: 366
Headquarters: London, United Kingdom
Website: kiniksa.com

Company description provided by Yahoo Finance.